Bellerophon therapeutics announces last patient has completed blinded treatment in phase 3 rebuild study for inopulse® in fibrotic interstitial lung disease

Warren, n.j., may 11, 2023 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing phase 3 rebuild study of inopulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fild).
BLPH Ratings Summary
BLPH Quant Ranking